Titlebook: Controversies in the Management of Gynecological Cancers; Jonathan A. Ledermann,Carien L. Creutzberg,Michael Book 2014 Springer-Verlag Lon

ERUPT

Book 2014selected either for their opposing views or for their ability to provide an opposite view or opinion to the other. The content will be evidence-based, illustrating contrasting evidence and scientific opinion in the literature. Each chapter will close on a summary indicating the direction of research needed to address the issues being discussed.

Hyaluronic-Acid

The Classification of Vegetationaff expertise, and the management of treatment-related toxicity. Nonetheless, the improved survival justifies consideration of IP therapy in appropriate patients. Multiple approaches to decrease toxicity, improve tolerability, and indentify key treatment components are currently being evaluated.

Defense

阻擋

Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?,aff expertise, and the management of treatment-related toxicity. Nonetheless, the improved survival justifies consideration of IP therapy in appropriate patients. Multiple approaches to decrease toxicity, improve tolerability, and indentify key treatment components are currently being evaluated.

新娘

Controversies in the Management of Advanced Vulvar Cancer,expert multidisciplinary opinion can guide management in order to obtain the therapeutic advantages of the modalities available and must be tailored to the patient- and tumor-related factors in each situation.

Gudgeon

Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer,e appropriate degree of surgical radicality, and need for lymphadenectomy, as well as the importance of fertility preservation in women with very early disease. We review the evidence for the need for adjuvant therapies and the optimum regimens particularly addressing the impact on younger women and long-term treatment sequelae in survivors.

Fracture

Irremediable

When Should Surgery Be Performed for the First-Line Treatment of Advanced Ovarian Cancer?,en following the surgery or as neoadjuvant treatment prior to surgery. This review will tease out the pros and cons of either management strategy based on the current evidence available and make recommendations for future research in the area.

LUCY

劇毒